Abstract | INTRODUCTION: This retrospective, observational study aimed to analyze and assess adherence, persistence, dosing, and use of concomitant medications of seven self-administered target drugs ( abatacept, golimumab, secukinumab, tocilizumab, ustekinumab, apremilast, and tofacitinib) that are currently available in Canada for the treatment of inflammatory arthritis (IA). METHODS: We used IQVIA's longitudinal claims databases, which include private drug plans and public plans. Patients with IA identified using a proprietary indication algorithm who initiated treatment with any of the target drugs between January 2015 and February 2019 were selected and followed for 12 months. RESULTS: CONCLUSION: This study identified substantial differences in patient baseline characteristics. Patients on injectable biologics were more likely to be adherent compared with those on oral drugs, possibly owing to longer dosing intervals. Other outcomes at 12 months appeared similar as evidenced by tapering of concomitant medications, although differences in persistence and dose escalation were noted.
|
Authors | Francois Nantel, Juejing Ling, Meagan Rachich, Odalis Asin-Milan, Brad Millson, Shane Golden, Huijuan Yang, Purva Barot, Allen J Lehman |
Journal | Rheumatology and therapy
(Rheumatol Ther)
Vol. 9
Issue 5
Pg. 1399-1420
(Oct 2022)
ISSN: 2198-6576 [Print] England |
PMID | 36045308
(Publication Type: Journal Article)
|
Copyright | © 2022. The Author(s). |